Connect Biopharma Holdings Limited (CNTB)
NASDAQ: CNTB · Real-Time Price · USD
0.8700
-0.0107 (-1.21%)
At close: Oct 9, 2026, 4:00 PM EDT
0.9000
+0.0300 (3.45%)
After-hours: Oct 9, 2026, 7:46 PM EDT
CNTB Revenue
Connect Biopharma Holdings had revenue of $2.77M in the quarter ending June 30, 2026, with 5,666.67% growth. This brings the company's revenue in the last twelve months to $2.95M, up 50.28% year-over-year. In the year 2025, Connect Biopharma Holdings had annual revenue of $64.00K, down -99.75%. That makes Connect Biopharma Holdings the 41,451st largest company in the world by revenue and 5,583rd in the United States.
Revenue (ttm)
$2.95M
Revenue Growth
+50.28%
P/S Ratio
18.55
Revenue / Employee
$46,141
Employees
64
Market Cap
54.79M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 64.00K | -25.97M | -99.75% |
| Dec 31, 2024 | 26.03M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Jan 1, 2022 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Xilio Therapeutics | 64.09M |
| Gossamer Bio | 53.29M |
| Alterity Therapeutics | 2.50M |
| RenovoRx | 1.98M |
| Mereo BioPharma Group | 500.00K |
| Clene | 197.00K |
| iBio, Inc. | 100.00K |
| Fractyl Health | 3.00K |
CNTB News
- 8 days ago - 3 Penny Stocks on Investors’ Radar, October 1 - TipRanks
- 9 days ago - Why Is Penny Stock Connect Biopharma (CNTB) Up 98% Today? - TipRanks
- 9 days ago - Connect Biopharma Holdings Transcript: Study result - Transcripts
- 9 days ago - Connect Biopharma Holdings Press release: Study result - Filings
- 9 days ago - Connect Biopharma Holdings Slides: Study result - Filings
- 9 days ago - Connect Biopharma announces results from global Phase 2 study of rademikibart - TheFly
- 9 days ago - Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation - GlobeNewsWire
- 17 days ago - Connect Biopharma price target lowered to $5 from $8 at Oppenheimer - TheFly